Stockreport

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Tonix Pharmaceuticals Holding Corp.  (TNXP) 
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm Check Earnings Report
US:NASDAQ Investor Relations: tonixpharma.com
PDF Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational prod [Read more]